China’s state-backed investors are increasing funding for artificial intelligence-based drug development companies as part of the country’s broader strategy to strengthen technological self-reliance in biotechnology and healthcare innovation.
Hangzhou-based METiS TechBio has developed an AI-designed oral treatment for neurological disorders that has successfully completed Phase III clinical trials, marking a major milestone for AI-driven pharmaceutical research in China.
Experts say continued government support and investment in AI medicine, research platforms, and biotech startups will help China build a competitive domestic pharmaceutical ecosystem and accelerate innovation in global healthcare technology.
Related stories:
